gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2023-33-4-70-75gastro-j-901Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГОВ, ГЕПАТОЛОГОВNATIONAL COLLEGE OF GASTROENTEROLOGISTS, HEPATOLOGISTSСовременные возможности применения лактулозы в клинической практикеModern Possibilities of Using Lactulose in Clinical Practicehttps://orcid.org/0000-0002-1395-9566ШептулинА. А.SheptulinA. A.

Шептулин Аркадий Александрович — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и гепатологии Института клинической медицины им. Н.В. Склифосовского 

119435, г. Москва, ул. Погодинская, 1, стр. 1

 

Arkadiy A. Sheptulin — Dr. Sci. (Med.), Professor, Head of the Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology

119435, Moscow, Pogodinskaya str., 1, build. 1

 

arkalshep@gmail.comФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation2023311020233347075Copyright © Шептулин А.А., 20232023Шептулин А.А.Sheptulin A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/901Цель публикации

Цель публикации.  Представить обзор   современных данных литературы о возможностях применения  лактулозы в клинической практике.

Основные положения

Основные положения.  Лактулоза является синтетическим дисахаридом, относящимся к классу осмотических слабительных. Официально разрешенными  показаниями  к  её назначению в Российской Федерации служат: функциональный запор (в том числе у детей, лиц пожилого и старческого возраста, беременных и женщин в послеродовом периоде),  обстипационный вариант синдрома раздраженного кишечника, необходимость смягчения консистенции кала  при геморрое и трещинах заднего прохода,  после операций на толстой кишке и аноректальной области, а также печеночная энцефалопатия.  Другие показания  включают в себя подготовку к колоноскопии, лечение и профилактику  нарушений состава кишечной микробиоты, профилактику   запоров у онкологических больных, получающих наркотические анальгетики, а  также  у пациентов, находящихся на искусственной вентиляции легких.  

Заключение

Заключение.  Лактулоза является высокоэффективным и безопасным препаратом,  сочетающим  осмотический слабительный эффект с активным пребиотическим действием, широко применяющимся в повседневной клинической практике.

Aim of  the publication

Aim of  the publication. To present an overview  of current literature data on the possibilities of application  of lactulose in clinical practice.

Key findings

Key findings. Lactulose is a synthetic disaccharide belonging to the class of osmotic laxatives. Officially  permitted indications for its appointment in Russian Federation are functional constipation (including in children, the elderly and senile, pregnant women and women in postpartum period), an obstipation type of irritable bowel syndrome, the need to soften the consistency of feces in hemorrhoids and anal fissures, after operations on the colon and anorectal area,   as well as hepatic encephalopathy.  Other  indications include preparation for colonoscopy, treatment and prevention of disorders of the intestinal microbiota, prevention  of constipation in oncological  patients receiving narcotic analgesics, as well as patients on artificial lung ventilation.

Conclusion

Conclusion. Lactulose is a highly effective  and safe drug, which combines osmotic laxative effect with expressed prebiotic action and is used in a wide clinical practice.

лактулозафункциональный запоробстипационный вариант синдрома раздраженного кишечникапеченочная энцефалопатияlactulosefunctional constipationobstipation type of irritable bowel syndromehepatic encephalopathyReferencesPranami D., Sharma R., Pathak H. Lactulose: a prebiotic, laxative and detoxifying agent. Drugs Ther Perspect. 2017; 33 (5): 228-233. DOI: 10.1007/s-40267-017-0386-zPranami D., Sharma R., Pathak H. Lactulose: a prebiotic, laxative and detoxifying agent. Drugs Ther Perspect. 2017; 33 (5): 228-233. DOI: 10.1007/s-40267-017-0386-zKasugai K., Iwai H., Kubayama N., Yoshikawa A., Fukudo S. Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study. J Gastroenterol. 2019; 54: 530-540. DOI: 10.1007/s00535-018-01545-7Kasugai K., Iwai H., Kubayama N., Yoshikawa A., Fukudo S. Efficacy and safety of a crystalline lactulose preparation (SK-1202) in Japanese patients with chronic constipation: a randomized, double-blind, placebo-controlled, dose-finding study. J Gastroenterol. 2019; 54: 530-540. DOI: 10.1007/s00535-018-01545-7Piche T., Dapoigny M. Comparative efficacy and safety of lactulose plus paraffin vs polyethylene glycol in functional constipation: a randomised clinical study. United European Gastroenterol J. 2020; 8 (8): 923-932. DOI: 10.1177/2050640620937913Piche T., Dapoigny M. Comparative efficacy and safety of lactulose plus paraffin vs polyethylene glycol in functional constipation: a randomised clinical study. United European Gastroenterol J. 2020; 8 (8): 923-932. DOI: 10.1177/2050640620937913Cao Y., Liu S.-M. Lactulose for the treatment of Chinese children with chronic constipation: A randomized controlled trial. Medicine (Baltimore). 2018; 97 (52): e13794. DOI: 10.1097/MD.0000000000013794Cao Y., Liu S.-M. Lactulose for the treatment of Chinese children with chronic constipation: A randomized controlled trial. Medicine (Baltimore). 2018; 97 (52): e13794. DOI: 10.1097/MD.0000000000013794Poddar U., Singh S., Pawaria A., Srivastava A., Yachha S. Aetiological spectrum, clinical differentiation and efficacy of polyethylene glycol over lactulose in children with constipation: Experience of 316 cases. Pediatr Child Health. 2019; 55 (2): 162-167. DOI:10.1111/jpc.14099Poddar U., Singh S., Pawaria A., Srivastava A., Yachha S. Aetiological spectrum, clinical differentiation and efficacy of polyethylene glycol over lactulose in children with constipation: Experience of 316 cases. Pediatr Child Health. 2019; 55 (2): 162-167. DOI:10.1111/jpc.14099Samasandaran G., Kawasalliya R.K., Rradha V., Dhivga R. Evaluation of management of functional constipation in children among South Indian population – cross sectional study. J Pharm Neg Res. 2022; 13 (6): 2277-2283. DOI: 10.47750/pnr.2022.s06.296Samasandaran G., Kawasalliya R.K., Rradha V., Dhivga R. Evaluation of management of functional constipation in children among South Indian population – cross sectional study. J Pharm Neg Res. 2022; 13 (6): 2277-2283. DOI: 10.47750/pnr.2022.s06.296Pont L.G., Fisher M., Williams K. Appropriate use of laxatives in the older person. Drugs and Aging. 2019; 36 (11): 999-1005. DOI: 10.1007/s40266-019-00701-9Pont L.G., Fisher M., Williams K. Appropriate use of laxatives in the older person. Drugs and Aging. 2019; 36 (11): 999-1005. DOI: 10.1007/s40266-019-00701-9Ивашкин В.Т., Мнацаканян М.Г., Остапенко В.С., Погромов А.П., Нековаль В.М., Полуэктова Е.А., Котовская Ю.В., Рунихина Н.К., Шарашкина Н.В., Царьков П.В., Ткачева Н.О., Беленков Ю.Н. Диагностика и лечение хронического запора у пациентов пожилого и старческого возраста: согласованное мнение экспертов. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021; 31 (4): 7-20. DOI: 10.22416/1382-4376-2021-31-4-7-20Ivashkin V.T., Mnatsakanyan M.G., Ostapenko V.S., Pogromov А.P., Nekoval V.M., Poluectova E.A., Kotovskaya Yu.V., Runikhina N.K., Sharashkina N.V., Tsarkov P.V., Tkacheva N.O., Belenkov Yu.N. Diagnosis and Тreatment of Elderly and Senile Chronic Constipation: an Expert Consensus. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021; 31 (4): 7-20. (In Russian)]. DOI: 10.22416/1382-4376-2021-31-4-7-20Li H., Zhang P., Xue Y. A comparison of the safety and efficacy of polyethylene glycol 4000 and lactulose for the treatment of constipation in pregnant women: a randomized controlled clinical study. Ann Palliat Med. 2020; 9 (6): 3785-3792. DOI: 10.21037/apm-20-1674Li H., Zhang P., Xue Y. A comparison of the safety and efficacy of polyethylene glycol 4000 and lactulose for the treatment of constipation in pregnant women: a randomized controlled clinical study. Ann Palliat Med. 2020; 9 (6): 3785-3792. DOI: 10.21037/apm-20-1674Huang P., Gou W.L., Wang X.T., Ding Y.L., He J., Wang C.H. Lactulose oral solution for the treatment of postpartum constipation. Regul Homeost Agents. 2016; 30 (2): 523-528Huang P., Gou W.L., Wang X.T., Ding Y.L., He J., Wang C.H. Lactulose oral solution for the treatment of postpartum constipation. Regul Homeost Agents. 2016; 30 (2): 523-528Meng S., Pan Y., Deng Q., Wang L., Chang Q. Efficacy and safety of lactulose on the treatment of puerperal constipation. Zhonghua Yi Xue Za Zhi. 2015; 95 (28): 2288-2890.Meng S., Pan Y., Deng Q., Wang L., Chang Q. Efficacy and safety of lactulose on the treatment of puerperal constipation. Zhonghua Yi Xue Za Zhi. 2015; 95 (28): 2288-2890.Zhou Y., Yang X., Fan L., Zhu Y., Jiang Y., Li Z. et al. Observations on the curative effect of lactulose for postpartum constipation based on a large sample study. J Clin Exp Med. 2015; 8 (10): 9167-9171.Zhou Y., Yang X., Fan L., Zhu Y., Jiang Y., Li Z. et al. Observations on the curative effect of lactulose for postpartum constipation based on a large sample study. J Clin Exp Med. 2015; 8 (10): 9167-9171.Flamm S.L. Complications of cirrhosis in primary care: recognition and management of hepatic encephalopathy. Am J Med Sci. 2018; 356 (3): 296 -303. DOI: 10.1016/j.amjms.2018.06.008Flamm S.L. Complications of cirrhosis in primary care: recognition and management of hepatic encephalopathy. Am J Med Sci. 2018; 356 (3): 296 -303. DOI: 10.1016/j.amjms.2018.06.008Ивашкин В.Т., Маевская М.В., Жаркова М.С., Жигалова С.Б., Киценко Е.А., Манукьян Г.А. Трухманов А.С., Маев И.В. Тихонов И.Н., Деева Т.А. Клинические рекомендации Российского общества по изучению печени и Российской гастроэнтерологической ассоциации по диагностике и лечению фиброза и цирроза печени и их осложнений. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021; 31 (6): 56-102. DOI: 10.22416/1382-4376-2021-31-6-56-102Ivashkin V.T., Maevskaya M.V., Zharkova M.S., Zhigalova S.B., Kitsenko E.A., Manukyan G.V., Trukhmanov A.S., Maev I.V., Tikhonov I. N., Deeva T.A. Clinical Recommendations of the Russian Scientific Liver Society and Russian Gastroenterological Association on Diagnosis and Treatment of Liver Fibrosis, Cirrhosis and Their Complications. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31 (6): 56–102. (in Russian)]. DOI: 10.22416/1382-4376-2021-31-6-56-102Elwir S., Rahimi R.S. Hepatic encephalopathy: An update on the pathophysiology and therapeutic options. J Clin Transl Hepatol. 2017; 5 (2): 142-151. DOI: 10.14218/JCTH.2016.00069Elwir S., Rahimi R.S. Hepatic encephalopathy: An update on the pathophysiology and therapeutic options. J Clin Transl Hepatol. 2017; 5 (2): 142-151. DOI: 10.14218/JCTH.2016.00069Wang J.Y., Bajaj J.S., Wang J.B., Shang J., Zhou X.M., Guo X.L. et al. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial. J Dig Dis. 2019; 20( 10): 547-556. DOI: 10.1111/1751-2980.12816Wang J.Y., Bajaj J.S., Wang J.B., Shang J., Zhou X.M., Guo X.L. et al. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial. J Dig Dis. 2019; 20( 10): 547-556. DOI: 10.1111/1751-2980.12816Dhiman R.K., Thumburu K.K., Verma N., Chopra M., Rathi S., Dutta U. et al. Comparative efficacy of treatment options for minimal hepatic encephalopathy: A systematic review and network meta-аnalysis. Clin Gastroenterol Hepatol. 2020; 18 (4): 800-812. e25. DOI: 10.1016/j.cgh.2019.08.047Dhiman R.K., Thumburu K.K., Verma N., Chopra M., Rathi S., Dutta U. et al. Comparative efficacy of treatment options for minimal hepatic encephalopathy: A systematic review and network meta-аnalysis. Clin Gastroenterol Hepatol. 2020; 18 (4): 800-812. e25. DOI: 10.1016/j.cgh.2019.08.047Rahimi S., Brown K.A., Flamm S.L., Brown R.S. Overt hepatic encephalopathy: current pharmacologic treatments and improving clinical outcomes. Am J Med. 2021; 134 (11): 1330-1338. DOI: 10.1016/j.amjmed.2021.06.007Rahimi S., Brown K.A., Flamm S.L., Brown R.S. Overt hepatic encephalopathy: current pharmacologic treatments and improving clinical outcomes. Am J Med. 2021; 134 (11): 1330-1338. DOI: 10.1016/j.amjmed.2021.06.007Hudson M., Schuchman M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019; 31 (4): 434-45. DOI: 10.1097/MEG.0000000000001311Hudson M., Schuchman M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019; 31 (4): 434-45. DOI: 10.1097/MEG.0000000000001311Aires F.T., Ramos P.T., Bernardo W.M. Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding. Rev Assoc Med Bras (1992). 2016; 62 (3): 243-247. DOI: 10.1590/1806-9282.62.03.243Aires F.T., Ramos P.T., Bernardo W.M. Efficacy of lactulose in the prophylaxis of hepatic encephalopathy in cirrhotic patients presenting gastrointestinal bleeding. Rev Assoc Med Bras (1992). 2016; 62 (3): 243-247. DOI: 10.1590/1806-9282.62.03.243Moon A.M., Kim H.P., Jiang Y., Lupu G., Bissram J.S., Barritt A.S., Tapper E.B. Systematic review and meta-analysis on the effects of lactulose and rifaximin on patient-reported outcomes in hepatic encephalopathy. J Gastroenterol. 2023; 118 (2): 284-293. DOI: 10.14309/ajg.0000000000002008Moon A.M., Kim H.P., Jiang Y., Lupu G., Bissram J.S., Barritt A.S., Tapper E.B. Systematic review and meta-analysis on the effects of lactulose and rifaximin on patient-reported outcomes in hepatic encephalopathy. J Gastroenterol. 2023; 118 (2): 284-293. DOI: 10.14309/ajg.0000000000002008Moneim M.A., Abdelaziz D.H., Nagy Y.I., Baki A.A., Attia A.S, Sabry N. Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis. Int J Clin Pract. 2021; 75 (11): e14807. DOI: 10.1111/ijcp.14807Moneim M.A., Abdelaziz D.H., Nagy Y.I., Baki A.A., Attia A.S, Sabry N. Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis. Int J Clin Pract. 2021; 75 (11): e14807. DOI: 10.1111/ijcp.14807Eriksen P.L., Djernes L., Vilstrup H., Ott H. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments. J Hepatol. 2023; 79 (2): 340-348. DOI: 10.1016/j.jhep.2023.03.042Eriksen P.L., Djernes L., Vilstrup H., Ott H. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments. J Hepatol. 2023; 79 (2): 340-348. DOI: 10.1016/j.jhep.2023.03.042Fu J., Gao Y., Shi L. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis. PLoS One. 2022; 17 ( 4): e0267647. DOI: 10.1371/journal.pone.0267647Fu J., Gao Y., Shi L. Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis. PLoS One. 2022; 17 ( 4): e0267647. DOI: 10.1371/journal.pone.0267647Butt N.I., Butt U.I., Kakar A.A.T.K., Malik T., Siddiqui A.M. Is lactulose plus rifaximin better than lactulose alone in the management of hepatic encephalopathy? J Coll Physicians Surg Pak. 2018; 28(2): 115-117. DOI: 10.29271/jcpsp.2018.02.115Butt N.I., Butt U.I., Kakar A.A.T.K., Malik T., Siddiqui A.M. Is lactulose plus rifaximin better than lactulose alone in the management of hepatic encephalopathy? J Coll Physicians Surg Pak. 2018; 28(2): 115-117. DOI: 10.29271/jcpsp.2018.02.115Ahire K., Sonawale A. Comparison of rifaximin plus lactulose with the lactulose alone for the treatment of hepatic encephalopathy. J Assoc Physicians India. 2017; 65 (8): 42-46.Ahire K., Sonawale A. Comparison of rifaximin plus lactulose with the lactulose alone for the treatment of hepatic encephalopathy. J Assoc Physicians India. 2017; 65 (8): 42-46.Hasan S., Datta S., Bhattacherjee S., Banik S., Saha S., Bandyopadhyay D. A randomized controlled trial comparing the efficacy of a combination of rfiaximin and lactulose with lactulose only in the treatment of overt hepatic encephalopathy. J Assoc Physicians India. 2018; 66 (1): 32-36.Hasan S., Datta S., Bhattacherjee S., Banik S., Saha S., Bandyopadhyay D. A randomized controlled trial comparing the efficacy of a combination of rfiaximin and lactulose with lactulose only in the treatment of overt hepatic encephalopathy. J Assoc Physicians India. 2018; 66 (1): 32-36. 28. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J.Hepatol. 2022; 77 (3): 807-824. DOI: 10.1016/j.jhep.2022.06.001EASL Clinical Practice Guidelines on the management of hepatic encephalopathy. J.Hepatol. 2022; 77 (3): 807-824. DOI: 10.1016/j.jhep.2022.06.001Karakan T. Tuohy K.M., Janssen-van Solingen G. Low-dose lactulose as a prebiotic for improved gut health and enhanced mineral absorption. Front Nutr. 2021; 8: 672925. DOI: 10.3389/fnut.2021.672925Karakan T. Tuohy K.M., Janssen-van Solingen G. Low-dose lactulose as a prebiotic for improved gut health and enhanced mineral absorption. Front Nutr. 2021; 8: 672925. DOI: 10.3389/fnut.2021.672925Sakai Y., Seki N., Hamano K., Ochi H., Abe F., Masuda K., Iino H. Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial. Benef Microbes. 2019; 10 (6): 629-639. DOI: 10.3920/BM2018.0174Sakai Y., Seki N., Hamano K., Ochi H., Abe F., Masuda K., Iino H. Prebiotic effect of two grams of lactulose in healthy Japanese women: a randomised, double-blind, placebo-controlled crossover trial. Benef Microbes. 2019; 10 (6): 629-639. DOI: 10.3920/BM2018.0174Nikolaou E., Kamilari E., Savkov D., Sergeev A., Zakharova I., Vogazianos P. et al. Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose. World J Pediatr. 2020; 16 (2): 168-176. DOI: 10.1007/s12519-019-00315-6Nikolaou E., Kamilari E., Savkov D., Sergeev A., Zakharova I., Vogazianos P. et al. Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose. World J Pediatr. 2020; 16 (2): 168-176. DOI: 10.1007/s12519-019-00315-6Chu N., Ling J., Jie H. Leung K., Poon E. The potential role of lactulose pharmacotherapy in the treatment and prevention of diabetes. Front Endocrinol (Lausanne). 2022; 13: 956203. DOI: 10.3389/fendo.2022.956203Chu N., Ling J., Jie H. Leung K., Poon E. The potential role of lactulose pharmacotherapy in the treatment and prevention of diabetes. Front Endocrinol (Lausanne). 2022; 13: 956203. DOI: 10.3389/fendo.2022.956203Yuanchao H., Xueping L., Tao L., Jianping N., Man M. The advantage of polyethylene glycol electrolyte solution combined with lactulose in patients with long interval preparation-to-colonoscopy. Turk J Gastroenterol. 2020; 31 (1): 23-29. DOI: 10.5152/tjg.2020.18888Yuanchao H., Xueping L., Tao L., Jianping N., Man M. The advantage of polyethylene glycol electrolyte solution combined with lactulose in patients with long interval preparation-to-colonoscopy. Turk J Gastroenterol. 2020; 31 (1): 23-29. DOI: 10.5152/tjg.2020.18888Zhang X., Chen Y., Chen Y., Zhu W., Tang C., Lamm S., Li L. Polyethylene glycol combined with lactulose has better efficacy than polyethylene glycol alone in bowel preparation before colonoscopy: A meta-analysis. Clinics (Sao Paulo). 2023; 78: 100172. DOI: 10.1016/j.clinsp.2023.100172Zhang X., Chen Y., Chen Y., Zhu W., Tang C., Lamm S., Li L. Polyethylene glycol combined with lactulose has better efficacy than polyethylene glycol alone in bowel preparation before colonoscopy: A meta-analysis. Clinics (Sao Paulo). 2023; 78: 100172. DOI: 10.1016/j.clinsp.2023.100172Jagdeep J., Sawant G., Lal P., Bains L. Oral lactulose vs. polyethylene glycol for bowel preparation in colonoscopy: a randomized controlled study. Cureus. 2021; 13(4): e14363 DOI: 10.7759/cureus.1436Jagdeep J., Sawant G., Lal P., Bains L. Oral lactulose vs. polyethylene glycol for bowel preparation in colonoscopy: a randomized controlled study. Cureus. 2021; 13(4): e14363 DOI: 10.7759/cureus.1436Li C.-X., Guo Y., Zhu Y.-J., Zhu J.-R., Xiao Q.S., Cgen D.-F., Lan C.-H.Li C.-X., Guo Y., Zhu Y.-J., Zhu J.-R., Xiao Q.S., Cgen D.-F., Lan C.-H.Comparison of polyethylene glycol versus lactulose oral solution for bowel preparation prior to colonoscopy. Gastroenterol Res Pract. 2019; 2019:2651450. DOI: 10.1155/2019/2651450Comparison of polyethylene glycol versus lactulose oral solution for bowel preparation prior to colonoscopy. Gastroenterol Res Pract. 2019; 2019:2651450. DOI: 10.1155/2019/2651450Nosek K., Leppert W., Nosek H., Wordliczek J., Onichimowski D.A. Сomparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. Drug Des Devel Ther. 2017; 11: 2409-2419. DOI: 10.2147/DDDT.S141007Nosek K., Leppert W., Nosek H., Wordliczek J., Onichimowski D.A. Сomparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients. Drug Des Devel Ther. 2017; 11: 2409-2419. DOI: 10.2147/DDDT.S141007Leppert W., Nosek K. Comparison of the quality of life of cancer patients with pain treated with oral controlled-release morphine and oxycodone and transdermal buprenorphine and fentanyl. Curr Pharm Des. 2019; 25 (30): 3216-3224. DOI: 10.2174/1381612825666190717091230Leppert W., Nosek K. Comparison of the quality of life of cancer patients with pain treated with oral controlled-release morphine and oxycodone and transdermal buprenorphine and fentanyl. Curr Pharm Des. 2019; 25 (30): 3216-3224. DOI: 10.2174/1381612825666190717091230De Azevedo R.P., Freites F.G.R., Ferreira E.V., De Azevedo L.C.P., Machado F.R. Daily laxative therapy reduces organ dysfunction in mechanically ventilated patients: a phase II randomized controlled trial. Crit Care. 2015; 19 (1): 329. DOI: 10.1186/s13054-015-1047-xDe Azevedo R.P., Freites F.G.R., Ferreira E.V., De Azevedo L.C.P., Machado F.R. Daily laxative therapy reduces organ dysfunction in mechanically ventilated patients: a phase II randomized controlled trial. Crit Care. 2015; 19 (1): 329. DOI: 10.1186/s13054-015-1047-xWang J., Jiang M., Hu Z., Lei Y., Zhu Y., Xiong H., He C. Lactulose regulates gut microbiota dysbiosis and promotes short-chain fatty acids production in acute pancreatitis patients with intestinal dysfunction. Вiomed Pharmacother. 2023; 163: 114769. DOI: 10.1016/j.biopha.2023.114769.Wang J., Jiang M., Hu Z., Lei Y., Zhu Y., Xiong H., He C. Lactulose regulates gut microbiota dysbiosis and promotes short-chain fatty acids production in acute pancreatitis patients with intestinal dysfunction. Вiomed Pharmacother. 2023; 163: 114769. DOI: 10.1016/j.biopha.2023.114769.Wang J., Jiang M., Hu Z., Lei Y., Zhu Y., Xiong H., He C. Lactulose regulates gut microbiota dysbiosis and promotes short-chain fatty acids production in acute pancreatitis patients with intestinal dysfunction. Вiomed Pharmacother. 2023; 163: 114769. DOI: 10.1016/j.biopha.2023.114769.

The authors declare that there are no conflicts of interest present.